U.S. and World News
:
Medical
:
Biotechnology
News
Osmetech Licenses Self-Assembling Monolayer (SAM) Technology to Minerva Biotechnologies Corporation
Mon, 18 Jun 2007, 23:36:00 EST
PASADENA, Calif. - June 18 (SEND2PRESS NEWSWIRE) -- Osmetech plc (LSE, AIM; OMH) today announced that it has granted a non-exclusive research license to Waltham, Massachusetts, US-based Minerva Biotechnologies Corporation ("Minerva") for use of Osmetech's self-assembling monolayer (SAM) technology in conjunction with Minerva's proprietary nanoparticle technology.
Osmetech, a fast developing, international molecular diagnostics business with operations in Boston and Pasadena, USA serves the high growth, near patient testing market and holds exclusive rights to the technology, which it exclusively licensed from Harvard University in 1997, and for which Minerva's founder and Chief Scientific Officer, Cynthia Bamdad, Ph.D., was the lead inventor. Financial details were not disclosed.
SAM technology is finding increasing merit in array and sensor technologies, particularly in electrochemical biosensing, where it is used to minimize background signal, provide for uniform functionalized attachment of molecules to surfaces and reduce nonspecific aggregation events. Minerva plans to use SAMs in tandem with its proprietary nanoparticle technology for signal enhancement, drug design, drug screening, and functional proteomics. Osmetech, by contrast, uses the technology in conjunction with nucleic acid analyte diagnostics. Late last year Osmetech licensed the same technology to Illinois-based Ohmx Corporation for use in non-nucleic acid analyte detection schemes, and is currently in dialog with a number of other companies that have also expressed interest, according to Edward Kreusser, Osmetech's VP of Intellectual Property and Legal Affairs.
"SAM use is by no means limited to electrochemical detection and is just one complementary piece of a much broader intellectual property position held in that field by Osmetech. In addition to the Harvard SAM IP, Osmetech also holds exclusive rights to very valuable biosensing patents owned by California Institute of Technology (Caltech), University of North Carolina, CMS and Concordia University, as well as a host of nonexclusive patent rights to a variety of related IP," says Kreusser.
James White, CEO of Osmetech said, "When Osmetech acquired Clinical Micro Sensors, Inc. (CMS) from Motorola, it came with a patent portfolio that had over $25 million spent on it and has over 145 granted patents worldwide with many more pending. This is another good example of our ability to maximize our economic return by actively out-licensing our significant intellectual property portfolio into non-diagnostic areas. We look forward to announcing other partnerships in the near future."
About Osmetech
Osmetech plc (www.osmetech.com) is an AIM-listed public company on the London Stock Exchange. The company is a fast developing, international molecular diagnostics business with operations in Boston and Pasadena in the US, serving the high growth, near patient testing market targeting small to medium sized hospitals. Osmetech has launched eSensor(R), an FDA cleared electrochemistry-based array system, for cystic fibrosis carrier detection and plan to launch a number of pharmacogenomic assays utilizing the same proprietary technology.
About Minerva Biotechnologies Corporation
Minerva Biotechnologies Corp. has developed a nanoparticle product line called Nano Vision. The first product is Nano Specs which are user-friendly nanoparticles that are functionalized to instantly capture and present any affinity tagged molecule. Minerva has proprietary nanoparticle applications in drug screening, disease diagnosis, and high throughput proteomics.
NEWS SOURCE: Osmetech plc
Send2Press® is the originating wire service for this story.
» Read More Biotechnology News
» Other Send2Press Industry News by Category
More Information and Media Contact:
For questions about this story, contact the news source:
»
Click Here for Contact Information
THE CONTENT OF THE ABOVE NEWS STORY WAS PROVIDED BY THE NEWS SOURCE WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS ABOUT THIS STORY CONTACT THE NEWS SOURCE AND NOT SEND2PRESS (THIS WEBSITE).
O T H E R R E S O U R C E S
T E R M S O F U S E
This article is Copr. © 1983-2008 Neotrope / Send2Press. Reproduction of this news article version requires written authorization. You may freely link to this article. Journalists (see the section "Journalist Resources" above) may use orig. news release as the basis for an article.
News Websites may republish the "news release" text version linked to above under "Journalist Resources" except must retain "Send2Press Newswire" as the source of this news if used verbatim. Websites which offer/sell PR or newswire services, or web promotion services, or "splogs" may NOT reprint our content in ANY form. Send2Press Newswire is a service mark of, and "Send2Press" is a registered trademark of, Neotrope. Creative Commons - Some Rights Reserved (3.0) - Attribution Required.
DISCLAIMER: the above article is believed accurate but not guaranteed, and is based on business news supplied by the source (Osmetech plc). The noted source is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements. Neotrope/Send2Press makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news and profiles are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope or Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.
REFERENCES: Osmetech Licenses Self-Assembling Monolayer (SAM) Technology to Minerva Biotechnologies Corporation, Osmetech plc, Minerva Biotechnologies Corporation, James White, Harvard SAM IP, self-assembling monolayer technology, nanoparticle technology, near patient testing market, functionalized attachment of molecules to surfaces and reduce nonspecific aggregation events, LSE AIM OMH, Jun 18, 2007.
VIEWED BY MEDIA (and public): 2188 times (3 today, 3 this week,
3 this month, 897 this year)
| FDA Grants Epeius Biotechnologies' Rexin-G A Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas |
| Epeius Biotechnologies Leads with Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma RandD Summit Conference in Boston |
| California Biotechnology Company Takes Aim at Pancreatic Cancer With an Advanced Phase I/II Clinical Trial Using Rexin-G(TM), a Targeted Injectable Gene Delivery System |
| Osmetech Licenses Self-Assembling Monolayer (SAM) Technology to Minerva Biotechnologies Corporation |
| Mark Whitacre, Ph.D. Joins Management Team at Cypress Systems, Inc. |
| Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology and the Clinical Development of its Lead Anti-Cancer Agent, Rexin-G(TM), at Upcoming Bioventure, Nanotechnology and Nanomedicine Conferences |
| Rexin-G(TM), The World's First Tumor-Targeted Gene Therapy Vector, Stymies Metastatic Cancer |
| Epeius Biotechnologies Affirms Leadership Role in The Development of Genetic Medicine |
| Reaction Biology Corp. Awarded NIH SBIR Grant for Kinase Radioisotope Microarray Screening Development |
| Key Organics Ltd and Reaction Biology Corporation Announce New Library Screening Format |
| Epeius Biotechnologies Establishes Corporate Headquarters in San Marino, California - Facilities Include a Clinical Research Unit Dedicated to Evaluating New Genetic Medicine for Cancer |
| Reaction Biology Corp. Awarded Phase II SBIR Grant for Drug Discovery |
| Clinical Trial For Pancreatic Cancer Opens at Mayo Clinic Using Tumor-Targeted Gene Therapy Vector |
| Reaction Biology Corporation Awarded NIH Kinase Grant |
| Phase I Clinical Trial for Advanced Colon and Pancreatic Cancer Opens in New York Using Rexin-G, the World's First Tumor-Targeted Gene Delivery Vector |
» View All News Channels
» Press Release Services
» Send2Press Home Page
|
|
|
 |
|
|
 |
ADVERTISEMENT
Promote Your Company to the Media and on This Website
Press release services from Neotrope®. Member BBB. Expert PR staff. Targeted solutions since 1983. Learn More
|
 |
| |
| | U.S. and World News |
| | Advertising and Marketing |
| | Aerospace and Aviation |
| | Agriculture and Farming |
| | Apple, Mac, iPod and iPhone |
| | Auction and Online Auctions |
| | Auto and Motorsports |
| | Banking and Finance |
| | Beauty Products |
| | Boating, Marine and Maritime |
| | Business |
| | Communication Arts |
| | Computing |
| | Construction and Building |
| | Corporate Social Responsibility - CSR |
| | Defense and Military |
| | Education and Schools |
| | Electronics |
| | Employment, HR and Outsourcing |
| | Energy, Oil and Gas |
| | Entertainment |
| | Environment and Ecology |
| | Facilities and Building Maintenance |
| | Family, Parenting and Children |
| | Food and Beverages |
| | General Editorial |
| | Global Aid and Relief |
| | Government |
| | Green Business |
| | Health, Diet and Fitness |
| | Home and Garden |
| | HVAC Heating and Cooling |
| | Insurance |
| | Internet and Websites |
| | Jewelry and Diamond |
| | Legal and Law |
| | Manufacturing |
| | Medical |
| | Alternative Medicine |
| | Biotechnology |
| | Cosmetic Surgery |
| | Dentistry |
| | Devices and Research |
| | Disabilities and 508 Compliance |
| | Drug Rehabilitation |
| | Drugs and Pharmaceuticals |
| | Fertility and IVF |
| | Hospitals and Nursing |
| | Long Term Care |
| | Medical and Health Products |
| | Medical Business Services |
| | Ophthalmology and Vision |
| | Private Practice and Medical Groups |
| | Surgery and Neurotechnology |
| | Mining and Metals |
| | Mortuary and Cemetery |
| | NonProfit and Charities |
| | Plastics and Composites |
| | Police, Fire and Rescue |
| | Real Estate |
| | Regional Events |
| | Religion and Churches |
| | Restaurant, Hotel and Hospitality |
| | Safety and Security Solutions |
| | Sciences |
| | Sports and Activities |
| | Stamps, Coins and Collectables |
| | Taxes and Accounting |
| | Telecommunications and VoIP |
| | Theme Parks and Attractions |
| | Trade Shows, Fairs and Expos |
| | Transportation |
| | Travel and Tourism |
| | U.S. Companies |
| | US and World History |
| | Veterinary and Pets |
| |
| | U.S. State Newswires |
| | Alabama Business |
| | Alaska Business |
| | Arizona Business |
| | California Business |
| | Colorado Business |
| | Connecticut Business |
| | Delaware Business |
| | Florida Business |
| | Georgia Business |
| | Hawaii Business |
| | Idaho Business |
| | Illinois Business |
| | Iowa Business |
| | Kansas Business |
| | Kentucky Business |
| | Maine Business |
| | Maryland Business |
| | Massachusetts Business |
| | Michigan Business |
| | Minnesota Business |
| | Mississippi Business |
| | Missouri Business |
| | Nebraska Business |
| | Nevada Business |
| | New Hampshire Business |
| | New Jersey Business |
| | New Mexico Business |
| | New York Business |
| | North Carolina Business |
| | Ohio Business |
| | Oklahoma Business |
| | Oregon Business |
| | Pennsylvania Business |
| | Puerto Rico Business |
| | South Carolina Business |
| | South Dakota Business |
| | Tennessee Business |
| | Texas Business |
| | Utah Business |
| | Vermont Business |
| | Virginia Business |
| | Washington D.C. Business |
| | Washington State Business |
| | West Virginia Business |
| | Wisconsin Business |
| |
| | Video News Releases |
| |
| | World Newswires |
| | Brazil Business |
| | Canada Business |
| | China Business |
| | Germany Business |
| | Italy Business |
| | Spain Business |
| | United Kingdom |
|
 |
Biotech Industry News
ContextEngine® Sponsors:
ContextEngine is a
reg. TM of Neotrope®
|
 |
|